HEALTHCARE BIOTECH COUNCIL

Cell & Gene Therapies

Cell and gene therapies, known as Advanced Therapy Medicinal Products or ATMPs, are a new generation of innovative medicines based on genes, cells or tissues. They have ground-breaking therapeutic potential, particularly in disease areas where treatment options are absent or inadequate. These therapies have in some cases the potential to cure challenging conditions with a one-off treatment.
These treatments that are often highly complex to develop and to deliver pose new questions in three areas:

Availability: How can EU regulatory systems further support the development and approval of advanced therapies?

Assessment: How can healthcare systems make the best assessment of the value offered by advanced therapies?

Affordability: How can healthcare systems respond to one-time therapies that are potentially curative and thus may have life-long benefit?

Our ATMP Working Group aims to raise the awareness of the transformative impact of cell and gene therapies for patients and society and the need for healthcare systems to adapt to ensure that patients across the EU can fully benefit of them. With our members who are leading the field in cell and gene therapies, EuropaBio offers EU decision-makers and other stakeholders unparalleled knowledge and first-hand insight into these innovative treatments from bench to bedside.

  • Inscripta Inc.
  • EV Biotech
  • Abolis
  • Olon Group
  • Health & Life Sciences cluster Bulgaria
  • ProductLife Group
  • MabDesign
 

BIOTECH NEWSLETTER


Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe

FOLLOW US HERE


Keep up with what is happening in the Biotech sector by connecting with us on social media!


facebook
twitter
instagram
linkedin
youtube
 

BIOTECH NEWSLETTER


Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
Become a member